Previous 10 | Next 10 |
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1...
Less than two years ago, Seattle Genetics (NASDAQ: SGEN) received a great deal of criticism for acquiring Cascadian Therapeutics to get its hands on an early clinical-stage cancer drug called tucatinib. Since then, the stock has climbed about 91% thanks to some impressive results from the ex...
Biotech stocks have been underperforming, but the drops in Puma Biotechnology (NASDAQ: PBYI) , Clovis Oncology (NASDAQ: CLVS) , and Regenxbio (NASDAQ: RGNX) have been downright jaw-dropping. Post-approval sales have been slow to materialize for Puma Biotech and Clovis Oncology, re...
On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...
Cancer drug sales are on track to post an impressive compound annual growth rate of 11.4% over the next five years, according to a report by EvaluatePharma. This double-digit growth rate is particularly noteworthy because cancer drug sales already dwarf all other pharma market segments by a wide...
Gainers: Asure Software (NASDAQ: ASUR ) +22% . SunLink Health Systems (NYSEMKT: SSY ) +10% . AgeX Therapeutics (NYSEMKT: AGE ) +9% . NIO (NYSE: NIO ) +9% . ATIF Holdings (NASDAQ: ATIF ) +8% . Frontier Communications Corporation (NASDAQ: FTR ) +8% . Nordic American Tankers Limit...
Puma Biotechnology (NASDAQ: PBYI ) discloses that Chief Commercial Officer Steven Lo will resign effective Friday, October 18, to accept the CEO job at another biotech. More news on: Puma Biotechnology, Inc., Healthcare stocks news, Stocks on the move, Read more ...
QIAGEN (NYSE: QGEN ) -18% on reporting preliminary Q3 results. More news on: QIAGEN N.V., Ocugen, Inc., Ambarella, Inc., Stocks on the move, Read more ...
ChromaDex (NASDAQ: CDXC ) initiated with Outperform rating and $8 (119% upside) price target at Sturdivant. More news on: ChromaDex Corporation, Satsuma Pharmaceuticals, Inc., SpringWorks Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Puma Biotechnology (NASDAQ: PBYI ) surges 13% in after-hours trading after the U.S. Food and Drug Administration approves a labeling supplement for Nerlynx (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer. More news on: Puma Biotechno...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...